ReviewPharmacoEconomics2013

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.

Janette Greenhalgh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.